<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Focal brainstem glioma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Focal brainstem glioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Focal brainstem glioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthias A Karajannis, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen J Marcus, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amar Gajjar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gliomas arising in the brainstem (midbrain, pons, and medulla oblongata) account for 10 to 20 percent of all central nervous system (CNS) tumors in children. Brainstem gliomas are heterogeneous, ranging from low-grade tumors that need little or no treatment to high-grade lesions that are rapidly fatal despite aggressive therapy [<a href="#rid1">1</a>]. Prognosis and treatment depend upon histologic features and the location within the brainstem  (<a class="graphic graphic_figure graphicRef53866" href="/d/graphic/53866.html" rel="external">figure 1</a>).</p><p>Focal brainstem gliomas typically arise in the midbrain and medulla, and typically are discrete, well-circumscribed tumors. Histologically, these tumors are most often pilocytic or diffuse astrocytomas, or rarely, gangliogliomas, all of which are considered low-grade tumors. Focal brainstem gliomas share many biologic features with posterior fossa and supratentorial low-grade gliomas, and significant advances in the analysis of the signaling pathways involved in their pathogenesis have been identified.</p><p>Focal brainstem gliomas are discussed here. Diffuse intrinsic pontine gliomas are discussed separately. (See  <a class="medical medical_review" href="/d/html/5229.html" rel="external">"Diffuse intrinsic pontine glioma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Brainstem tumors are more common in children than adults, with approximately 500 pediatric and 300 adult cases reported each year in the United States [<a href="#rid2">2-6</a>]. Brainstem gliomas account for approximately 13 percent of all intracranial neoplasms in children under the age of 14 years.</p><p>In children, the median age at diagnosis is five to nine years of age. Within this age group, brainstem malignancies are nearly as common as cerebral malignancies. The incidence is approximately equal between males and females [<a href="#rid7">7-10</a>].</p><p>The only known inheritable risk factor for both low-grade and high-grade brainstem gliomas is neurofibromatosis type 1. (See  <a class="medical medical_review" href="/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Other central nervous system neoplasms'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H2668272023"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>Focal brainstem gliomas typically arise in the midbrain and medulla, and typically are discrete, well-circumscribed tumors. Histologically, these tumors are most often pilocytic or diffuse astrocytomas, or rarely, gangliogliomas, all of which are considered low-grade tumors [<a href="#rid11">11</a>]. Especially in tumors with nonpilocytic histology, evidence of locally invasive growth or edema may be present. Focal brainstem gliomas share many biologic features with posterior fossa and supratentorial low-grade gliomas, including key molecular genetic changes. (See <a class="local">'Molecular genetics'</a> below.)</p><p>Up to 80 percent of brainstem gliomas that occur outside the pons are low grade (World Health Organization [WHO] grade 1 and 2 tumors,  (<a class="graphic graphic_table graphicRef109511" href="/d/graphic/109511.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef134980" href="/d/graphic/134980.html" rel="external">table 2</a>)) [<a href="#rid2">2,3,12-15</a>]. The remaining 20 percent are high-grade gliomas [<a href="#rid12">12,13</a>]. The WHO grading system for gliomas is based upon both histopathologic and molecular features [<a href="#rid16">16</a>] (see  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"</a>). Low-grade astrocytomas are characterized by varying degrees of cellularity and occasional nuclear atypia, although they lack other features of malignancy. The histology of grade 1 tumors (pilocytic astrocytomas) is distinctive, usually consisting of biphasic microcystic areas interspersed between more compacted and cellular areas with extensive fibrillary processes and associated Rosenthal fibers (composed of alpha-B crystallin) [<a href="#rid17">17</a>]. Occasionally there may be a large macrocystic structure containing a mural nodule. Pilocytic astrocytomas can possess a few mitoses and vascular proliferation without elevation to a higher grade. (See  <a class="medical medical_review" href="/d/html/5202.html" rel="external">"Uncommon brain tumors", section on 'Pilocytic astrocytoma'</a>.)</p><p class="headingAnchor" id="H2806884413"><span class="h2">Molecular genetics</span><span class="headingEndMark"> — </span>Whenever possible, histologic diagnosis should be supplemented by molecular diagnostics, which can provide important diagnostic, prognostic, and therapeutic information [<a href="#rid16">16,18-20</a>]. (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Key molecular diagnostic tests'</a>.)</p><p>Advances in the molecular analysis of pediatric low-grade gliomas, including those of the brainstem, have identified frequent recurring alterations in the mitogen-activated protein kinase (MAPK) pathway, including characteristic duplications involving the <em>BRAF</em> gene in pilocytic astrocytomas (<em>KIAA1549-BRAF</em> fusion) and mutation (<em>BRAF</em> V600E), as well as activating mutations and fusions in fibroblast growth factor receptor (<em>FGFR</em>) genes. Molecular profiling therefore provides important diagnostic, prognostic, and therapeutic information [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Most children with low-grade brainstem gliomas have a relatively long history of minor symptoms and signs, which may have been present for many years [<a href="#rid2">2,3,12-15,22,23</a>].</p><p>Signs and symptoms generally reflect the location of the tumor, the presence of hydrocephalus, and/or the age of the child. Most tumors produce some neck stiffness or discomfort; some patients may even present with torticollis. (See  <a class="medical medical_review" href="/d/html/6462.html" rel="external">"Acquired torticollis in children", section on 'Central nervous system tumor'</a> and  <a class="medical medical_review" href="/d/html/6433.html" rel="external">"Approach to neck stiffness in children", section on 'Central nervous system lesions'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Small focal tumors of the midbrain or medulla usually present insidiously, with a long history of localizing findings such as an isolated cranial nerve deficit or contralateral hemiparesis. Signs and symptoms of raised intracranial pressure (ICP) are uncommon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dorsally exophytic tumors and focal tumors of the tectum, the dorsal aspect of the rostral or upper midbrain, typically present with headache, vomiting, and ataxia secondary to aqueductal occlusion and hydrocephalus. Cranial nerve deficits are seen in approximately one-half of patients, but long tract signs are distinctly unusual. Symptoms referable to brainstem dysfunction (eg, Parinaud syndrome) may occur  (<a class="graphic graphic_table graphicRef81227" href="/d/graphic/81227.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/6257.html" rel="external">"Ocular gaze disorders", section on 'Parinaud syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medullary tumors can be associated with cranial nerve dysfunction, dysphagia, nasal speech, and apnea. Patients may also have weakness, ataxia, nausea, and vomiting. Rarely, a focal pontine tumor can produce facial and auditory nerve dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervicomedullary junction tumors can cause hemiparesis or quadriparesis from upper motor neuron dysfunction, as well as weakness, muscle atrophy, and loss of reflexes from lower motor nerve dysfunction. Hydrocephalus is uncommon, but patients may have apnea, sensory deficits, headache, vomiting, and cranial neuropathies [<a href="#rid14">14,23</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Imaging studies are the standard initial method to diagnose and classify brainstem tumors.</p><p>Findings on magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) often permit the differentiation of circumscribed low-grade brainstem gliomas from other tumor types including high-grade lesions [<a href="#rid12">12,24,25</a>]. A stereotactic biopsy is indicated if the diagnosis cannot be established by imaging. Tumors that are felt to be resectable are typically diagnosed at the time of surgery, without a preceding biopsy. (See <a class="local">'Surgery'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">MRI appearance</span><span class="headingEndMark"> — </span>MRI of the brain with and without contrast is the method of choice to image tumors in the brainstem, since many of these lesions are isointense on computed tomography (CT) [<a href="#rid23">23,26,27</a>].</p><p>On MRI, focal low-grade brainstem gliomas most often appear as masses of limited size (&lt;2 cm) that may be cystic, well demarcated, noninfiltrating, and without associated edema. They are typically isointense or hypointense on T1-weighted images, hyperintense on T2-weighted images, and enhance uniformly and brightly with intravenous contrast [<a href="#rid24">24,25,28,29</a>]. Diffusion tensor imaging (DTI) and white matter tractography are very useful in documenting axonal degeneration of the motor and sensory tracts in focal brainstem tumors. These imaging sequences may assist in surgical planning for biopsy or tumor debulking. Additionally, advanced imaging may assist in prognostication of possible functional tract recovery following therapy [<a href="#rid30">30</a>]. Focal tumors of the midbrain can contain calcifications and enhance poorly with contrast [<a href="#rid3">3</a>].</p><p>MRI is particularly helpful for tectal gliomas, whose imaging appearance typically is uniform, with a nonenhancing thickening of the tectal plate  (<a class="graphic graphic_diagnosticimage graphicRef120736" href="/d/graphic/120736.html" rel="external">image 1</a>) [<a href="#rid26">26,28</a>]. The noninfiltrative nature of these masses, their dorsal exophytic growth pattern, and associated hydrocephalus all suggest a low-grade tumor. The pattern of enhancement may also lend support, as grade 1 tumors are often diffusely enhanced with gadolinium, grade 2 tumors are often nonenhancing, while high-grade pontine gliomas often demonstrate ring enhancement [<a href="#rid31">31</a>]. Tectal plate tumors are usually diagnosed based upon their characteristic MRI appearance and presence of hydrocephalus [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/5229.html" rel="external">"Diffuse intrinsic pontine glioma", section on 'Neuroimaging'</a>.)</p><p>The MRI signal characteristics of cervicomedullary lesions are similar to those of other low-grade astrocytomas, with intense T2 signal and low T1 signal [<a href="#rid23">23</a>]. A cystic area is usually present, often within a dorsal exophytic component  (<a class="graphic graphic_diagnosticimage graphicRef120735" href="/d/graphic/120735.html" rel="external">image 2</a>). Tumors with a dorsally exophytic component are usually associated with hydrocephalus [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Magnetic resonance spectroscopy</span><span class="headingEndMark"> — </span>MRS is a supplemental diagnostic technique for brain tumors and can be helpful for the differentiation of locally infiltrative brain tumors from other well-circumscribed intracranial lesions. MRS measurement of tumor-associated choline and N-acetylaspartate and their ratio (Cho:NAA) may help distinguish high-grade from low-grade lesions [<a href="#rid32">32-34</a>].</p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of focal brainstem gliomas requires a consideration of the anatomic location of the tumor, which determines both symptoms and accessibility to surgical resection. The long-term prognosis of patients with brainstem low-grade glioma is excellent [<a href="#rid35">35</a>].</p><p>Optimal treatment requires a team that includes experienced neurosurgeons, radiation oncologists, and neurooncologists, as well as psychosocial workers, educational specialists, and physical and occupational therapists. Such multidisciplinary care is best delivered at a specialized tertiary care center with a dedicated neurooncology program.</p><p class="headingAnchor" id="H11"><span class="h2">Therapeutic approaches</span><span class="headingEndMark"> — </span>Surgical resection, radiation therapy (RT), and chemotherapy each can play a role in the management of patients with focal brainstem gliomas.</p><p class="headingAnchor" id="H12"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Historically, the location of focal brainstem gliomas in one of the most eloquent areas of the central nervous system (CNS) was thought to preclude surgery, and most patients were treated with RT.</p><p>However, improved intraoperative imaging and guidance technologies have enhanced the surgeon's ability to maximally resect these tumors while preserving normal tissue and function [<a href="#rid36">36-43</a>]. Although there are no randomized trials, resection has become the preferred treatment for focal brainstem gliomas in surgically accessible locations, such as at the cervicomedullary junction in selected cases [<a href="#rid44">44</a>] and for dorsal exophytic lesions. Positron emission tomography (PET) imaging can improve the localization of higher-grade regions within brainstem tumors and help guide the location of biopsy [<a href="#rid45">45</a>]. In patients for whom resection is contraindicated, stereotactic biopsy can provide important histologic and molecular information to guide further therapy in both pediatric [<a href="#rid46">46</a>] and adult patients [<a href="#rid47">47</a>].</p><p>Approximately 30 percent of resected tumors will progress and require further therapy. A second operation can be considered for patients with surgically accessible disease [<a href="#rid48">48,49</a>]. For others, the most reasonable option is chemotherapy in children and focal RT in adults.</p><p class="headingAnchor" id="H13"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>RT provides an important alternative for focal brainstem lesions that are surgically inaccessible. Treatment with external beam RT, using standard fractionation, controls approximately 50 to 70 percent of focal lesions [<a href="#rid2">2,50-53</a>]. With this approach, the total radiation dose is 54 Gy, delivered in once-daily fractions, five days a week for six weeks to a limited volume with a 0.5 to 1 cm margin.</p><p>Advances in the use of RT for brainstem gliomas have focused on decreasing morbidity by limiting the radiation dose to normal tissue. Newer conformal RT techniques, including stereotactic radiosurgery (SRS), fractionated stereotactic radiotherapy (SRT), intensity-modulated radiation therapy (IMRT), volumetric modulated arc radiotherapy (VMAT), and proton radiotherapy, help to minimize radiation to the normal brain at large and are particularly important for the delivery of radiation to brainstem tumors, which are often in close proximity to critical structures such as the pituitary gland and the optic nerves.</p><p>Although these approaches have not been compared with conventional external beam RT in patients with focal low-grade brainstem gliomas, clinical practice has been influenced by trials performed in more common tumors, such as low-grade optic pathway gliomas or medulloblastomas. Selection of a specific technique in patients with brainstem tumors is individualized based on the availability of the technology and consideration of the technique that would provide the best coverage of the tumor with sparing of critical organs and normal tissue.</p><p>Although RT may result in long-term progression-free survival, it can be associated with significant morbidity, especially in very young children. Long-term effects include reduced growth and other endocrinopathies secondary to dose to the pituitary gland and hypothalamus, cognitive and hearing deficits, vascular stenosis leading to stroke, as well as a risk of secondary treatment-induced malignancy. Thus, RT should be limited to older children and adults whenever possible to minimize late morbidity. The delayed complications of cranial irradiation are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>Chemotherapy is playing an increasing role in the treatment of brainstem gliomas in order to avoid or delay using RT in children [<a href="#rid54">54-58</a>].</p><p>Few clinical studies have evaluated the efficacy of chemotherapy in treating focal low-grade gliomas of the brainstem. As with RT, clinical practice has been influenced by the experience in treating supratentorial and fourth ventricular low-grade gliomas.</p><p>Tumor growth can be stabilized by chemotherapy and can have a dramatically positive impact on quality of life by delaying or obviating the need for RT in young children [<a href="#rid59">59-62</a>]. This is achieved without reducing the efficacy of definitive treatment, as tumors that progress on or after chemotherapy have not been found to be less responsive to RT.</p><p>Approximately 40 percent of children who are treated with weekly <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> for low-grade gliomas have an objective response to treatment, and a higher percentage may achieve periods of disease stability [<a href="#rid60">60,61,63</a>]. In one report, for example, the two- and three-year progression-free survival rates were 75 and 68 percent, respectively [<a href="#rid61">61</a>]. Similar results have been obtained with other chemotherapy regimens (eg, 6-thioguanine, <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, <a class="drug drug_general" data-topicid="9569" href="/d/drug information/9569.html" rel="external">lomustine</a>, and vincristine [TPCV]) [<a href="#rid64">64</a>].</p><p>The optimal chemotherapy regimen for pediatric low-grade gliomas is unclear, and most trials have included patients with tumors throughout the brain and spine, not just those localized to the brainstem. The weekly <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>/<a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> regimen has been compared with TPCV in a national trial of pediatric CNS low-grade gliomas, and these regimens have approximately equal efficacy [<a href="#rid65">65</a>]. Single-agent monthly carboplatin without vincristine appears to have similar efficacy [<a href="#rid66">66,67</a>]. In most centers, carboplatin-based chemotherapy is considered the first choice for upfront therapy, given its more favorable toxicity profile compared with TPCV.</p><p>Some preliminary data suggest a possible role for <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> [<a href="#rid68">68</a>], <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> [<a href="#rid69">69</a>], metronomic therapy [<a href="#rid70">70</a>], <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid71">71</a>], and <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> [<a href="#rid72">72</a>] in patients who have progressed after other chemotherapy or RT. Since all of these studies were conducted in small groups of heterogenous low-grade glioma patients, more definitive clinical trials are required to assess their full activity and long-term toxicity.</p><p class="headingAnchor" id="H2060666615"><span class="h3">Targeted therapies</span><span class="headingEndMark"> — </span>Agents that target specific pathways in pediatric low-grade gliomas are under investigation and, for tumors harboring certain variants, approved for use. As an example, the combination of <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, a mitogen-activated protein kinase kinase (MEK) inhibitor, and <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, a BRAF inhibitor, is approved in the United States for use in children 1 year of age and older with <em>BRAF</em> V600E-mutant low-grade glioma who require systemic therapy. The treatment approach in such tumors located in the brainstem is similar to the approach for tumors in other areas of the brain. (See  <a class="medical medical_review" href="/d/html/5202.html" rel="external">"Uncommon brain tumors", section on 'Pilocytic astrocytoma'</a>.) </p><p class="headingAnchor" id="H3258319680"><span class="h3">Intracystic therapies</span><span class="headingEndMark"> — </span>Cyst expansion in pediatric low-grade gliomas can cause significant morbidity. In patients with enlarging cysts where the solid component of the tumor is stable, there is little evidence that systemic chemotherapy or radiotherapy is an optimal approach to control further cyst expansion. A number of approaches in which therapy to the cyst is provided through a reservoir have been developed; these include radioactive phosphorus (P32) [<a href="#rid73">73</a>], <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid74">74</a>], and interferon alfa [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Tectal tumors</span><span class="headingEndMark"> — </span>Small tectal gliomas arising in the dorsal midbrain typically cause aqueductal obstruction, with symptoms of increased intracranial pressure (ICP) [<a href="#rid13">13</a>]. The initial treatment for tectal tumors is shunting the cerebrospinal fluid (CSF) with a ventriculoperitoneal (VP) drainage, or, preferably, third ventriculostomy [<a href="#rid76">76</a>]. The latter procedure avoids the implantation of a foreign object and can be performed as a day surgery [<a href="#rid26">26,59,77-81</a>].</p><p>The natural history of tectal gliomas is usually prolonged, and even modern neurosurgical methods may be associated with significant morbidity [<a href="#rid82">82</a>]. A biopsy is not needed unless atypical features are present, and many low-grade tectal gliomas can be observed initially without any intervention other than shunting [<a href="#rid78">78,83-85</a>]. Among tectal gliomas that have been sampled pathologically, most have histopathologic features similar to pilocytic astrocytoma. In a series including molecular analysis, evidence of <em>BRAF</em> fusion or <em>BRAF</em> V600E mutation was detected in 25 and 8 percent of tectal gliomas, respectively, with no tumor harboring a histone H3 K27M mutation [<a href="#rid86">86</a>].</p><p>A high percentage of patients who undergo shunting alone remain progression free without further therapy [<a href="#rid26">26,78,80,83</a>]. In a single-institution series of 46 children with tectal glioma over a 25-year period, 86 percent of patients required CSF diversion, 23 percent received RT, and 18 percent required systemic therapy [<a href="#rid86">86</a>]. Ten-year progression-free and overall survival were 49 and 84 percent, respectively.</p><p>Risk factors for progression of tectal gliomas include size greater than 10 cm<sup>3</sup>, contrast enhancement, and cystic changes at presentation [<a href="#rid86">86-88</a>].</p><p>Following relief of increased ICP, persistently symptomatic or progressively enlarging tumors should be treated with surgery (rarely possible), chemotherapy, or focal RT if chemotherapy is not possible [<a href="#rid89">89</a>]. Progression in very young children is managed with a trial of chemotherapy with the aim of stabilizing growth. (See <a class="local">'Chemotherapy'</a> above.)</p><p class="headingAnchor" id="H16"><span class="h2">Dorsal exophytic gliomas</span><span class="headingEndMark"> — </span>The approach to dorsal exophytic gliomas relies upon surgical resection whenever possible. Safe resection generally requires intraoperative guidance to achieve a maximal degree of tumor resection. However, since many of these lesions arise from the floor of the fourth ventricle, there may not be a definite tumor-brainstem interface, and even an optimal resection can leave a small rind of tumor behind on the floor of the fourth ventricle.</p><p>Although resection is often incomplete, the majority of children do well long term. In two separate series, 12 of 16 and 7 of 10 patients undergoing surgery alone remained free of progression with median follow-up duration of 113 and 26 months, respectively [<a href="#rid15">15,29</a>]. In both series, recurrent tumors were subsequently controlled by reexcision, RT, or both.</p><p>Routine postoperative RT is not indicated and should only be considered for the rare patient with a high-grade lesion or for those with low-grade lesions who progress rapidly after initial resection [<a href="#rid2">2</a>]. Later recurrences can be managed with reresection, RT, chemotherapy, and genotype-specific targeted therapies in some cases.</p><p>In addition to low-grade astrocytomas, gangliogliomas are observed in this region [<a href="#rid90">90</a>]. The diagnostic and therapeutic approaches to these tumors are similar to those used for low-grade astrocytoma. Approximately 60 percent of gangliogliomas harbor the <em>BRAF</em> V600E mutation [<a href="#rid91">91</a>] and are thus eligible for combination MEK/BRAF inhibitor therapy in some cases. (See  <a class="medical medical_review" href="/d/html/5202.html" rel="external">"Uncommon brain tumors", section on 'Ganglioglioma and gangliocytoma'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Tumors of the medulla</span><span class="headingEndMark"> — </span>Tumors that are intrinsic to the medulla, or at the level of the facial colliculus (located on the pontine floor of the fourth ventricle), are generally not approached surgically. At these locations, resection would be associated with unacceptable morbidity [<a href="#rid2">2</a>]. Thus, chemotherapy, or in adults RT, is the preferred approach.</p><p class="headingAnchor" id="H18"><span class="h2">Cervicomedullary tumors</span><span class="headingEndMark"> — </span>These tumors are often considered tumors of the spinal cord and are treated similarly. (See  <a class="medical medical_review" href="/d/html/5227.html" rel="external">"Spinal cord tumors", section on 'Astrocytomas'</a>.)</p><p>Surgery is the treatment of choice, and a gross total resection can be achieved in approximately 75 percent of cases [<a href="#rid92">92</a>]. The probability of long-term survival is excellent for the typical low-grade lesion, and postoperative chemotherapy or RT is not indicated [<a href="#rid23">23,93</a>]. Lesions that recur or progress after surgery are treated with chemotherapy (in children) or radiotherapy (in adults). Since many gangliogliomas in this location harbor the <em>BRAF</em> V600E mutation, resection or biopsy may provide important genetic information to guide targeted therapy, if needed [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Cystic tumors</span><span class="headingEndMark"> — </span>Some low-grade gliomas present with cystic components. In this situation, their biologic behavior may be independent of the solid component of the tumor. Accumulation of cyst fluid can produce neurologic dysfunction and symptoms, necessitating therapy.</p><p>Management of these cysts can be difficult. Primary therapy includes drainage. Approaches to treatment of reaccumulated fluid include repeated drainage, an attempt to remove the cyst wall, systemic chemotherapy for low-grade gliomas, focal RT, or occasionally intracavitary instillation of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid74">74,95</a>] or interferon alfa [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H20"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Long-term survival for children with brainstem low-grade gliomas approaches 100 percent in many series [<a href="#rid35">35,96</a>]. On the other hand, progression-free survival is approximately 40 to 70 percent [<a href="#rid35">35,65,97,98</a>], and chronic disability is common. This disability results from both treatment-related morbidity and tumor-related neurologic damage resulting from compression of the brainstem, long nerve tracts, and cranial nerves [<a href="#rid14">14,15,92,99,100</a>]. Molecular features have emerged as significant prognostic markers, including the identification of cyclin dependent kinase inhibitor 2A (<em>CDKN2A</em>) deletion as a high-risk feature [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Neurologic and cognitive outcome</span><span class="headingEndMark"> — </span>Survivors of childhood central nervous system (CNS) tumors generally have some degree of neurocognitive deficit. The extent of the deficit primarily depends upon the age at the time of treatment and the dose of radiation. These complications are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6253.html" rel="external">"Overview of the management of central nervous system tumors in children", section on 'Long-term morbidity'</a>.)</p><p>For survivors of focal brainstem tumors, the duration of symptoms at presentation and the severity of the tumor-associated disability are the most important variables in predicting long-term neurologic outcome [<a href="#rid13">13-15,101</a>]. Tumors that require placement of a ventriculoperitoneal (VP) shunt have added long-term morbidities associated with chronic catheter placement, including the risk of infection and the need for surgical revision of the shunt.</p><p>Survival is the most important long-term outcome, but other factors must be considered since most patients will survive for decades. With a number of other treatment options available, surgical efforts should be directed at confirming tumor biology; minimizing morbidity is the primary goal rather than complete tumor removal. Similarly, the delayed morbidity of radiation therapy (RT) supports the use of slightly less effective therapies (eg, chemotherapy) for which long-term morbidity is significantly less.</p><p>Treatment strategies must be individualized and consider physical, genetic, and cognitive factors. As an example, for some patients, particularly those with neurofibromatosis type 1, treatment may be deferred if tumor progression remains limited and asymptomatic. For most other patients, incompletely resected lesions will recur, and treatment should probably not be deferred.</p><p>Mounting evidence suggests that multidisciplinary evaluation of CNS tumor survivors is important. In addition to the physical and medical issues associated with therapy (eg, seizure control, physical and occupational rehabilitation), attention must be paid to cognition. Even patients receiving only surgery for a low-grade brainstem glioma can have significant functional impairment, indicating that all patients should be considered at risk [<a href="#rid102">102</a>]. To deal with these issues, psychologists, neuropsychologists, and school liaison specialists are needed. Since childhood is a fluid period of attainment of different abilities, age-appropriate performance at one time point does not ensure continued attainment of future milestones.</p><p>Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=5191" target="_blank">Children's Oncology Group</a> [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H22"><span class="h1">BRAINSTEM GLIOMAS IN ADULTS</span><span class="headingEndMark"> — </span>Brainstem gliomas are less common in adults than in children [<a href="#rid85">85,104,105</a>]. With the exception of dorsal midbrain (tectal) gliomas, their clinical behavior more closely resembles supratentorial gliomas in adults [<a href="#rid85">85,104,106</a>]. (See  <a class="medical medical_review" href="/d/html/5228.html" rel="external">"Clinical presentation, diagnosis, and initial surgical management of high-grade gliomas"</a> and  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"</a> and  <a class="medical medical_review" href="/d/html/5198.html" rel="external">"Treatment and prognosis of IDH-mutant astrocytomas in adults"</a>.)</p><p>Tectal gliomas are rare in adults, making up less than 10 percent of brainstem tumors. Patients may be asymptomatic, with the mass discovered incidentally, or they may present with secondary obstructive hydrocephalus. As in children, hydrocephalus is managed with ventriculoperitoneal (VP) shunting. Some patients require radiation therapy for progressive enlargement, while those who are asymptomatic are often observed with serial imaging. The natural history in adults is not well described, with median survival exceeding 10 years [<a href="#rid104">104,107</a>].</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathology</strong> – Focal brainstem gliomas are uncommon tumors typically seen in children. Most of these arise in the midbrain  (<a class="graphic graphic_diagnosticimage graphicRef120736" href="/d/graphic/120736.html" rel="external">image 1</a>), medulla, or cervicomedullary junction  (<a class="graphic graphic_diagnosticimage graphicRef120735" href="/d/graphic/120735.html" rel="external">image 2</a>). Pathologically, most are low-grade gliomas. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimaging</strong> – On MRI, focal low-grade brainstem gliomas most often appear as masses of limited size (&lt;2 cm) that may be cystic, well demarcated, noninfiltrating, and without associated edema  (<a class="graphic graphic_diagnosticimage graphicRef120735" href="/d/graphic/120735.html" rel="external">image 2</a>). Tectal gliomas have a distinct appearance, with uniform, nonenhancing thickening of the tectal plate  (<a class="graphic graphic_diagnosticimage graphicRef120736" href="/d/graphic/120736.html" rel="external">image 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Whenever possible, histologic diagnosis should be supplemented by molecular diagnostics, which can provide important diagnostic, prognostic, and therapeutic information. Molecular targeted therapy is being studied in ongoing clinical trials and represents a rapidly emerging treatment option for pediatric low-grade glioma patients. (See <a class="local">'Molecular genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nontectal tumors</strong> – For patients with newly diagnosed focal brainstem gliomas other than tectal gliomas, we suggest surgical resection if this can be accomplished without excessive surgical morbidity (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent2">For patients with tumors that are unresectable or only partially resectable, radiation therapy (RT) offers an alternative to surgery. Because of the risk of delayed complications from RT, chemotherapy is warranted in order to avoid or delay radiation in children. (See <a class="local">'Radiation therapy'</a> above and <a class="local">'Chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tectal gliomas</strong> – For patients with small tectal gliomas arising in the dorsal midbrain, symptoms generally are due to increased intracranial pressure (ICP) from aqueductal obstruction. In this situation, shunting the cerebrospinal fluid (CSF) using a third ventriculostomy to relieve the hydrocephalus is required. Since the natural history of these lesions tends to be prolonged, we suggest that these patients be observed without any definitive intervention following shunting in the absence of evidence of progression (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Tectal tumors'</a> above.)</p><p></p><p class="headingAnchor" id="H276682654"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mark Kieran, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Green AL, Kieran MW. Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors. Curr Oncol Rep 2015; 17:436.</a></li><li><a class="nounderline abstract_t">Freeman CR, Farmer JP. Pediatric brain stem gliomas: A review. Int J Radiat Oncol Biol Phys 1998; 40:265.</a></li><li><a class="nounderline abstract_t">Rubin G, Michowitz S, Horev G, et al. Pediatric brain stem gliomas: An update. Childs Nerv Syst 1998; 14:167.</a></li><li><a class="nounderline abstract_t">Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20 Suppl 4:iv1.</a></li><li><a class="nounderline abstract_t">Packer RJ. Brain tumors in children. Arch Neurol 1999; 56:421.</a></li><li><a class="nounderline abstract_t">Selvapandian S, Rajshekhar V, Chandy MJ. Brainstem glioma: Comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien) 1999; 141:721.</a></li><li><a class="nounderline abstract_t">Withrow DR, Berrington de Gonzalez A, Lam CJK, et al. Trends in Pediatric Central Nervous System Tumor Incidence in the United States, 1998-2013. Cancer Epidemiol Biomarkers Prev 2019; 28:522.</a></li><li><a class="nounderline abstract_t">Duffner PK, Cohen ME, Myers MH, Heise HW. Survival of children with brain tumors: SEER Program, 1973-1980. Neurology 1986; 36:597.</a></li><li><a class="nounderline abstract_t">Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75:2186.</a></li><li><a class="nounderline abstract_t">Kaba SE, Kyritsis AP. Recognition and management of gliomas. Drugs 1997; 53:235.</a></li><li><a class="nounderline abstract_t">Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer 2000; 89:1569.</a></li><li><a class="nounderline abstract_t">Epstein FJ, Farmer JP. Brain-stem glioma growth patterns. J Neurosurg 1993; 78:408.</a></li><li><a class="nounderline abstract_t">Epstein F, Constantini S. Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 1996; 24:24.</a></li><li><a class="nounderline abstract_t">Robertson PL, Allen JC, Abbott IR, et al. Cervicomedullary tumors in children: A distinct subset of brainstem gliomas. Neurology 1994; 44:1798.</a></li><li><a class="nounderline abstract_t">Pollack IF, Hoffman HJ, Humphreys RP, Becker L. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg 1993; 78:859.</a></li><li class="breakAll">Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</li><li><a class="nounderline abstract_t">Goldman JE, Corbin E. Rosenthal fibers contain ubiquitinated alpha B-crystallin. Am J Pathol 1991; 139:933.</a></li><li><a class="nounderline abstract_t">Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 2015; 33:1015.</a></li><li><a class="nounderline abstract_t">Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol 2017; 35:2934.</a></li><li><a class="nounderline abstract_t">Qaddoumi I, Orisme W, Wen J, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 2016; 131:833.</a></li><li><a class="nounderline abstract_t">Ryall S, Zapotocky M, Fukuoka K, et al. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell 2020; 37:569.</a></li><li><a class="nounderline abstract_t">Epstein F, Wisoff J. Intra-axial tumors of the cervicomedullary junction. J Neurosurg 1987; 67:483.</a></li><li><a class="nounderline abstract_t">Young Poussaint T, Yousuf N, Barnes PD, et al. Cervicomedullary astrocytomas of childhood: clinical and imaging follow-up. Pediatr Radiol 1999; 29:662.</a></li><li><a class="nounderline abstract_t">Pierre-Kahn A, Hirsch JF, Vinchon M, et al. Surgical management of brain-stem tumors in children: results and statistical analysis of 75 cases. J Neurosurg 1993; 79:845.</a></li><li><a class="nounderline abstract_t">Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg 1990-1991; 16:73.</a></li><li><a class="nounderline abstract_t">Pollack IF, Pang D, Albright AL. The long-term outcome in children with late-onset aqueductal stenosis resulting from benign intrinsic tectal tumors. J Neurosurg 1994; 80:681.</a></li><li><a class="nounderline abstract_t">Boydston WR, Sanford RA, Muhlbauer MS, et al. Gliomas of the tectum and periaqueductal region of the mesencephalon. Pediatr Neurosurg 1991-1992; 17:234.</a></li><li><a class="nounderline abstract_t">Sun B, Wang CC, Wang J. MRI characteristics of midbrain tumours. Neuroradiology 1999; 41:158.</a></li><li><a class="nounderline abstract_t">Khatib ZA, Heideman RL, Kovnar EH, et al. Predominance of pilocytic histology in dorsally exophytic brain stem tumors. Pediatr Neurosurg 1994; 20:2.</a></li><li><a class="nounderline abstract_t">Helton KJ, Weeks JK, Phillips NS, et al. Diffusion tensor imaging of brainstem tumors: axonal degeneration of motor and sensory tracts. J Neurosurg Pediatr 2008; 1:270.</a></li><li><a class="nounderline abstract_t">Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: A report from the Children's Cancer Group. Neurosurgery 1993; 33:1026.</a></li><li><a class="nounderline abstract_t">Warren KE, Frank JA, Black JL, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000; 18:1020.</a></li><li><a class="nounderline abstract_t">Astrakas LG, Zurakowski D, Tzika AA, et al. Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res 2004; 10:8220.</a></li><li><a class="nounderline abstract_t">Purohit B, Kamli AA, Kollias SS. Imaging of adult brainstem gliomas. Eur J Radiol 2015; 84:709.</a></li><li><a class="nounderline abstract_t">Upadhyaya SA, Koschmann C, Muraszko K, et al. Brainstem Low-Grade Gliomas in Children-Excellent Outcomes With Multimodality Therapy. J Child Neurol 2017; 32:194.</a></li><li><a class="nounderline abstract_t">Roessler K, Ungersboeck K, Aichholzer M, et al. Frameless stereotactic lesion contour-guided surgery using a computer-navigated microscope. Surg Neurol 1998; 49:282.</a></li><li><a class="nounderline abstract_t">Hata N, Dohi T, Iseki H, Takakura K. Development of a frameless and armless stereotactic neuronavigation system with ultrasonographic registration. Neurosurgery 1997; 41:608.</a></li><li><a class="nounderline abstract_t">Kollias SS, Bernays R, Marugg RA, et al. Target definition and trajectory optimization for interactive MR-guided biopsies of brain tumors in an open configuration MRI system. J Magn Reson Imaging 1998; 8:143.</a></li><li><a class="nounderline abstract_t">Moriarty TM, Kikinis R, Jolesz FA, et al. Magnetic resonance imaging therapy. Intraoperative MR imaging. Neurosurg Clin N Am 1996; 7:323.</a></li><li><a class="nounderline abstract_t">Tronnier VM, Wirtz CR, Knauth M, et al. Intraoperative diagnostic and interventional magnetic resonance imaging in neurosurgery. Neurosurgery 1997; 40:891.</a></li><li><a class="nounderline abstract_t">Teo C, Siu TL. Radical resection of focal brainstem gliomas: is it worth doing? Childs Nerv Syst 2008; 24:1307.</a></li><li><a class="nounderline abstract_t">Recinos PF, Sciubba DM, Jallo GI. Brainstem tumors: where are we today? Pediatr Neurosurg 2007; 43:192.</a></li><li><a class="nounderline abstract_t">Wisoff JH, Sanford RA, Heier LA, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 2011; 68:1548.</a></li><li><a class="nounderline abstract_t">Di Maio S, Gul SM, Cochrane DD, et al. Clinical, radiologic and pathologic features and outcome following surgery for cervicomedullary gliomas in children. Childs Nerv Syst 2009; 25:1401.</a></li><li><a class="nounderline abstract_t">Pirotte BJ, Lubansu A, Massager N, et al. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg 2007; 107:392.</a></li><li><a class="nounderline abstract_t">Pérez-Gómez JL, Rodríguez-Alvarez CA, Marhx-Bracho A, Rueda-Franco F. Stereotactic biopsy for brainstem tumors in pediatric patients. Childs Nerv Syst 2010; 26:29.</a></li><li><a class="nounderline abstract_t">Rachinger W, Grau S, Holtmannspötter M, et al. Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only. J Neurol Neurosurg Psychiatry 2009; 80:1134.</a></li><li><a class="nounderline abstract_t">Bowers DC, Krause TP, Aronson LJ, et al. Second surgery for recurrent pilocytic astrocytoma in children. Pediatr Neurosurg 2001; 34:229.</a></li><li><a class="nounderline abstract_t">Krieger MD, Gonzalez-Gomez I, Levy ML, McComb JG. Recurrence patterns and anaplastic change in a long-term study of pilocytic astrocytomas. Pediatr Neurosurg 1997; 27:1.</a></li><li><a class="nounderline abstract_t">Albright AL, Guthkelch AN, Packer RJ, et al. Prognostic factors in pediatric brain-stem gliomas. J Neurosurg 1986; 65:751.</a></li><li><a class="nounderline abstract_t">Shibamoto Y, Takahashi M, Dokoh S, et al. Radiation therapy for brain stem tumor with special reference to CT feature and prognosis correlations. Int J Radiat Oncol Biol Phys 1989; 17:71.</a></li><li><a class="nounderline abstract_t">Schild SE, Stafford SL, Brown PD, et al. The results of radiotherapy for brainstem tumors. J Neurooncol 1998; 40:171.</a></li><li><a class="nounderline abstract_t">Schulz-Ertner D, Debus J, Lohr F, et al. Fractionated stereotactic conformal radiation therapy of brain stem gliomas: outcome and prognostic factors. Radiother Oncol 2000; 57:215.</a></li><li><a class="nounderline abstract_t">Fuss M, Hug EB, Schaefer RA, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys 1999; 45:1117.</a></li><li><a class="nounderline abstract_t">McAllister B, Archambeau JO, Nguyen MC, et al. Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities. Int J Radiat Oncol Biol Phys 1997; 39:455.</a></li><li><a class="nounderline abstract_t">Khoo VS, Oldham M, Adams EJ, et al. Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. Int J Radiat Oncol Biol Phys 1999; 45:415.</a></li><li><a class="nounderline abstract_t">Cardinale RM, Benedict SH, Wu Q, et al. A comparison of three stereotactic radiotherapy techniques; ARCS vs. noncoplanar fixed fields vs. intensity modulation. Int J Radiat Oncol Biol Phys 1998; 42:431.</a></li><li><a class="nounderline abstract_t">Ma L, Xia P, Verhey LJ, Boyer AL. A dosimetric comparison of fan-beam intensity modulated radiotherapy with Gamma Knife stereotactic radiosurgery for treating intermediate intracranial lesions. Int J Radiat Oncol Biol Phys 1999; 45:1325.</a></li><li><a class="nounderline abstract_t">Kato T, Sawamura Y, Tada M, et al. Cisplatin/vincristine chemotherapy for hypothalamic/visual pathway astrocytomas in young children. J Neurooncol 1998; 37:263.</a></li><li><a class="nounderline abstract_t">Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993; 11:850.</a></li><li><a class="nounderline abstract_t">Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86:747.</a></li><li><a class="nounderline abstract_t">Bouffet E, Amat D, Devaux Y, Desuzinges C. Chemotherapy for spinal cord astrocytoma. Med Pediatr Oncol 1997; 29:560.</a></li><li><a class="nounderline abstract_t">Ronghe M, Hargrave D, Bartels U, et al. Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer 2010; 55:471.</a></li><li><a class="nounderline abstract_t">Prados MD, Edwards MS, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997; 32:235.</a></li><li><a class="nounderline abstract_t">Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:2641.</a></li><li><a class="nounderline abstract_t">Gururangan S, Cavazos CM, Ashley D, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 2002; 20:2951.</a></li><li><a class="nounderline abstract_t">Dodgshun AJ, Maixner WJ, Heath JA, et al. Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy. Int J Cancer 2016; 138:481.</a></li><li><a class="nounderline abstract_t">Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012; 30:1358.</a></li><li><a class="nounderline abstract_t">Gururangan S, Fangusaro J, Poussaint TY, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2014; 16:310.</a></li><li><a class="nounderline abstract_t">Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 2014; 61:636.</a></li><li><a class="nounderline abstract_t">Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 2011; 29:324.</a></li><li><a class="nounderline abstract_t">Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007; 110:1542.</a></li><li><a class="nounderline abstract_t">Hood TW, Shapiro B, Taren JA. Treatment of cystic astrocytomas with intracavitary phosphorus 32. Acta Neurochir Suppl (Wien) 1987; 39:34.</a></li><li><a class="nounderline abstract_t">Disabato JA, Handler MH, Strain JD, et al. Successful use of intracavitary bleomycin for low-grade astrocytoma tumor cyst. Pediatr Neurosurg 1999; 31:246.</a></li><li><a class="nounderline abstract_t">Steinbok P, Hukin J. Intracystic treatments for craniopharyngioma. Neurosurg Focus 2010; 28:E13.</a></li><li><a class="nounderline abstract_t">Li KW, Roonprapunt C, Lawson HC, et al. Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas. Neurosurg Focus 2005; 18:E2.</a></li><li><a class="nounderline abstract_t">Vandertop WP, Hoffman HJ, Drake JM, et al. Focal midbrain tumors in children. Neurosurgery 1992; 31:186.</a></li><li><a class="nounderline abstract_t">May PL, Blaser SI, Hoffman HJ, et al. Benign intrinsic tectal "tumors" in children. J Neurosurg 1991; 74:867.</a></li><li><a class="nounderline abstract_t">Robertson PL, Muraszko KM, Brunberg JA, et al. Pediatric midbrain tumors: a benign subgroup of brainstem gliomas. Pediatr Neurosurg 1995; 22:65.</a></li><li><a class="nounderline abstract_t">Squires LA, Allen JC, Abbott R, Epstein FJ. Focal tectal tumors: management and prognosis. Neurology 1994; 44:953.</a></li><li><a class="nounderline abstract_t">Wellons JC 3rd, Tubbs RS, Banks JT, et al. Long-term control of hydrocephalus via endoscopic third ventriculostomy in children with tectal plate gliomas. Neurosurgery 2002; 51:63.</a></li><li><a class="nounderline abstract_t">Lapras C, Bognar L, Turjman F, et al. Tectal plate gliomas. Part I: Microsurgery of the tectal plate gliomas. Acta Neurochir (Wien) 1994; 126:76.</a></li><li><a class="nounderline abstract_t">Bowers DC, Georgiades C, Aronson LJ, et al. Tectal gliomas: natural history of an indolent lesion in pediatric patients. Pediatr Neurosurg 2000; 32:24.</a></li><li><a class="nounderline abstract_t">Dağlioğlu E, Cataltepe O, Akalan N. Tectal gliomas in children: the implications for natural history and management strategy. Pediatr Neurosurg 2003; 38:223.</a></li><li><a class="nounderline abstract_t">Yeh DD, Warnick RE, Ernst RJ. Management strategy for adult patients with dorsal midbrain gliomas. Neurosurgery 2002; 50:735.</a></li><li><a class="nounderline abstract_t">Liu APY, Harreld JH, Jacola LM, et al. Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis. Acta Neuropathol Commun 2018; 6:101.</a></li><li><a class="nounderline abstract_t">Ternier J, Wray A, Puget S, et al. Tectal plate lesions in children. J Neurosurg 2006; 104:369.</a></li><li><a class="nounderline abstract_t">Kershenovich A, Silman Z, de Rungs D, et al. Tectal Lesions in Children: A Long-Term Follow-Up Volumetric Tumor Growth Analysis in Surgical and Nonsurgical Cases. Pediatr Neurosurg 2016; 51:69.</a></li><li><a class="nounderline abstract_t">Stark AM, Fritsch MJ, Claviez A, et al. Management of tectal glioma in childhood. Pediatr Neurol 2005; 33:33.</a></li><li><a class="nounderline abstract_t">Lagares A, Gómez PA, Lobato RD, et al. Ganglioglioma of the brainstem: report of three cases and review of the literature. Surg Neurol 2001; 56:315.</a></li><li><a class="nounderline abstract_t">MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4:e7887.</a></li><li><a class="nounderline abstract_t">Weiner HL, Freed D, Woo HH, et al. Intra-axial tumors of the cervicomedullary junction: surgical results and long-term outcome. Pediatr Neurosurg 1997; 27:12.</a></li><li><a class="nounderline abstract_t">Epstein F, McCleary EL. Intrinsic brain-stem tumors of childhood: surgical indications. J Neurosurg 1986; 64:11.</a></li><li><a class="nounderline abstract_t">Puget S, Alshehri A, Beccaria K, et al. Pediatric infratentorial ganglioglioma. Childs Nerv Syst 2015; 31:1707.</a></li><li><a class="nounderline abstract_t">Giovanini MA, Mickle JP. Long-term access to cystic brain stem lesions using the Ommaya reservoir: technical case report. Neurosurgery 1996; 39:404.</a></li><li><a class="nounderline abstract_t">Bandopadhayay P, Bergthold G, London WB, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 2014; 61:1173.</a></li><li><a class="nounderline abstract_t">Fisher PG, Tihan T, Goldthwaite PT, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008; 51:245.</a></li><li><a class="nounderline abstract_t">Klimo P Jr, Pai Panandiker AS, Thompson CJ, et al. Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience. J Neurosurg Pediatr 2013; 11:274.</a></li><li><a class="nounderline abstract_t">Abbott R, Shiminski-Maher T, Wisoff JH, Epstein FJ. Intrinsic tumors of the medulla: surgical complications. Pediatr Neurosurg 1991-1992; 17:239.</a></li><li><a class="nounderline abstract_t">Wang C, Zhang J, Liu A, et al. Surgical treatment of primary midbrain gliomas. Surg Neurol 2000; 53:41.</a></li><li><a class="nounderline abstract_t">Mulhern RK, Heideman RL, Khatib ZA, et al. Quality of survival among children treated for brain stem glioma. Pediatr Neurosurg 1994; 20:226.</a></li><li><a class="nounderline abstract_t">Ris MD, Beebe DW, Armstrong FD, et al. Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children's Oncology Group. J Clin Oncol 2008; 26:4765.</a></li><li><a class="nounderline abstract_t">Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.</a></li><li><a class="nounderline abstract_t">Guillamo JS, Monjour A, Taillandier L, et al. Brainstem gliomas in adults: Prognostic factors and classification. Brain 2001; 124:2528.</a></li><li><a class="nounderline abstract_t">Landolfi JC, Thaler HT, DeAngelis LM. Adult brainstem gliomas. Neurology 1998; 51:1136.</a></li><li><a class="nounderline abstract_t">Salmaggi A, Fariselli L, Milanesi I, et al. Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol 2008; 255:171.</a></li><li><a class="nounderline abstract_t">Reyes-Botero G, Mokhtari K, Martin-Duverneuil N, et al. Adult brainstem gliomas. Oncologist 2012; 17:388.</a></li></ol></div><div id="topicVersionRevision">Topic 5191 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25702179" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457808" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric brain stem gliomas: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660117" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pediatric brain stem gliomas: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199329" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Brain tumors in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10481783" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30464022" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in Pediatric Central Nervous System Tumor Incidence in the United States, 1998-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3703257" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Survival of children with brain tumors: SEER Program, 1973-1980.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7697611" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028743" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recognition and management of gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013373" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433142" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Brain-stem glioma growth patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8817612" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Practical decisions in the treatment of pediatric brain stem tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936224" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cervicomedullary tumors in children: a distinct subset of brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487066" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487066" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1656764" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rosenthal fibers contain ubiquitinated alpha B-crystallin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25667294" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28727518" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810070" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32289278" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3309202" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intra-axial tumors of the cervicomedullary junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460326" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cervicomedullary astrocytomas of childhood: clinical and imaging follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8246052" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Surgical management of brain-stem tumors in children: results and statistical analysis of 75 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2132928" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Brain stem gliomas: a classification system based on magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8151347" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The long-term outcome in children with late-onset aqueductal stenosis resulting from benign intrinsic tectal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1822688" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gliomas of the tectum and periaqueductal region of the mesencephalon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10206156" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : MRI characteristics of midbrain tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142279" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Predominance of pilocytic histology in dorsally exophytic brain stem tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377301" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diffusion tensor imaging of brainstem tumors: axonal degeneration of motor and sensory tracts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8133987" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694552" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623597" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25641008" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Imaging of adult brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27810966" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Brainstem Low-Grade Gliomas in Children-Excellent Outcomes With Multimodality Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9508116" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Frameless stereotactic lesion contour-guided surgery using a computer-navigated microscope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9310978" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Development of a frameless and armless stereotactic neuronavigation system with ultrasonographic registration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500274" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Target definition and trajectory optimization for interactive MR-guided biopsies of brain tumors in an open configuration MRI system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8726445" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Magnetic resonance imaging therapy. Intraoperative MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149246" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intraoperative diagnostic and interventional magnetic resonance imaging in neurosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18563419" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Radical resection of focal brainstem gliomas: is it worth doing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409788" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Brainstem tumors: where are we today?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21368693" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636567" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical, radiologic and pathologic features and outcome following surgery for cervicomedullary gliomas in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18459902" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19784659" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Stereotactic biopsy for brainstem tumors in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19520698" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423771" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Second surgery for recurrent pilocytic astrocytoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486830" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recurrence patterns and anaplastic change in a long-term study of pilocytic astrocytomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3772472" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prognostic factors in pediatric brain-stem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2745210" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Radiation therapy for brain stem tumor with special reference to CT feature and prognosis correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892099" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The results of radiotherapy for brainstem tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054526" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fractionated stereotactic conformal radiation therapy of brain stem gliomas: outcome and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613303" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308950" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487565" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788426" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A comparison of three stereotactic radiotherapy techniques; ARCS vs. noncoplanar fixed fields vs. intensity modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613329" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A dosimetric comparison of fan-beam intensity modulated radiotherapy with Gamma Knife stereotactic radiosurgery for treating intermediate intracranial lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9524084" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cisplatin/vincristine chemotherapy for hypothalamic/visual pathway astrocytomas in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487049" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126887" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9324344" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chemotherapy for spinal cord astrocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535831" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049885" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665535" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089224" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Phase II study of carboplatin in children with progressive low-grade gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26235348" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393086" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311632" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123865" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149652" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17705175" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314383" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of cystic astrocytomas with intracavitary phosphorus 32.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10681679" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Successful use of intracavitary bleomycin for low-grade astrocytoma tumor cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367357" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Intracystic treatments for craniopharyngioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048288" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1308661" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Focal midbrain tumors in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2033445" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Benign intrinsic tectal "tumors" in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7710975" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pediatric midbrain tumors: a benign subgroup of brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190303" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Focal tectal tumors: management and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182436" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term control of hydrocephalus via endoscopic third ventriculostomy in children with tectal plate gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8042559" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tectal plate gliomas. Part I: Microsurgery of the tectal plate gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10765135" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Tectal gliomas: natural history of an indolent lesion in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686764" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Tectal gliomas in children: the implications for natural history and management strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904023" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Management strategy for adult patients with dorsal midbrain gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30253793" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776370" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Tectal plate lesions in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26789512" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Tectal Lesions in Children: A Long-Term Follow-Up Volumetric Tumor Growth Analysis in Surgical and Nonsurgical Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15876519" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Management of tectal glioma in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11750003" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Ganglioglioma of the brainstem: report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924296" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Profiling critical cancer gene mutations in clinical tumor samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486831" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Intra-axial tumors of the cervicomedullary junction: surgical results and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3941334" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Intrinsic brain-stem tumors of childhood: surgical indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26351224" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pediatric infratentorial ganglioglioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8832683" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term access to cystic brain stem lesions using the Ommaya reservoir: technical case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482038" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18386785" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Outcome analysis of childhood low-grade astrocytomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23289916" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1822689" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Intrinsic tumors of the medulla: surgical complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697232" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Surgical treatment of primary midbrain gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8043460" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Quality of survival among children treated for brain stem glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779602" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15576413" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701605" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Brainstem gliomas in adults: prognostic factors and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781543" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Adult brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18293027" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Natural history and management of brainstem gliomas in adults. A retrospective Italian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22382458" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Adult brainstem gliomas.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
